Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages 2312-2318

  Blumenschein Jr , George R ^a   Paulus, Rebecca ^c   Curran, Walter J ^d   Robert, Francisco ^e   Fossella, Frank ^a   Werner Wasik, Maria ^d   Herbst, Roy S ^a   Doescher, Philip O ^f   Choy, Hak ^b   Komaki, Ritsuko ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Statistical Center   (United States)

^d University Hospital   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL;

ADD ON THERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALLERGY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD DISEASE; BONE MARROW DISEASE; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CHEMORADIOTHERAPY; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; EAR DISEASE; ENDOCRINE DISEASE; ESOPHAGITIS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEPATOBILIARY DISEASE; HUMAN; HYPOXIA; INFECTION; INOPERABLE CANCER; LOADING DRUG DOSE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PAIN; PANCREAS DISEASE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SEPSIS; SKIN DISEASE; SOFT TISSUE DISEASE; TREATMENT DURATION; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT COMPLIANCE;

EID: 79959195283     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.7875     Document Type: Article

References (37)

1. American Cancer Society: Cancer Facts and Figures 2008. http://www.cancer.org/Research/CancerFactsFigures/cancer-facts-figures-2008
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
3. Molina JR, Yang P, Cassivi SD, et al: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584-594, 2008 (Pubitemid 351720831)
4. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
5. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999 (Pubitemid 29415225)
6. CurranWJr, Scott C, Langer C, et al: Phase III comparison of sequential vs concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19:98, 2000 (abstr 1891)
7. Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23: 5883-5891, 2005
8. Benhar M, Engelberg D, Levitzki A: Cisplatin-induced activation of the EGF receptor. Oncogene 21:8723-8731, 2002 (Pubitemid 36132393)
9. Sumitomo M, Asano T, Asakuma J, et al: ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 10:794-801, 2004 (Pubitemid 38174018)
10. Liang K, Ang KK, Milas L, et al: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57:246-254, 2003 (Pubitemid 36959763)
11. Goel S, Hidalgo M, Perez-Soler R: EGFR inhibitor-mediated apoptosis in solid tumors. J Exp Ther Oncol 6:305-320, 2007 (Pubitemid 350104820)
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
13. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107:1207-1218, 2006
14. Bruns CJ, Harbison MT, Davis DW, et al: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-1948, 2000
15. Baselga J, Norton L, Masui H, et al: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333, 1993 (Pubitemid 23249725)
16. Ciardiello F, Bianco R, Damiano V, et al: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5:909-916, 1999 (Pubitemid 29180844)
17. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000 (Pubitemid 30106623)
18. Raben D, Helfrich B, Chan DC, et al: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11:795-805, 2005 (Pubitemid 40116908)
19. Saleh MN, Raisch KP, Stackhouse MA, et al: Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14:451-463, 1999 (Pubitemid 30029793)
20. Bianco C, Bianco R, Tortora G, et al: Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6:4343-4350, 2000
21. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000
22. Robert F, Blumenschein G, Herbst RS, et al: Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23: 9089-9096, 2005
23. Rosell R, Robinet G, Szczesna A, et al: Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19:362-369, 2008 (Pubitemid 351201721)
24. Lynch TJ, Patel T, Dreisbach L, et al: A randomized multicenter phase III study of cetuximab (Erbitux[R]) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic nonsmall cell lung cancer (NSCLC). J Thorac Oncol, 3:S340-S341, 2007 (suppl 8)
25. Thienelt CD, Bunn PA Jr, Hanna N, et al: Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23:8786-8793, 2005 (Pubitemid 46211524)
26. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
27. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
28. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
29. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989 (Pubitemid 19272848)
30. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
31. Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley & Sons, 1982
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
33. Kalbfleish JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980
34. Gandara DR, Chansky K, Albain KS, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010, 2003
35. Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456, 2008
36. Gill GN, Kawamoto T, Cochet C, et al: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7760, 1984 (Pubitemid 14081190)
37. Hanna N, Lilenbaum R, Ansari R, et al: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24:5253-5258, 2006 (Pubitemid 46631370)